Cargando…
Pan-Lysyl Oxidase Inhibitor PXS-5505 Ameliorates Multiple-Organ Fibrosis by Inhibiting Collagen Crosslinks in Rodent Models of Systemic Sclerosis
Systemic sclerosis (SSc) is characterised by progressive multiple organ fibrosis leading to morbidity and mortality. Lysyl oxidases play a vital role in the cross-linking of collagens and subsequent build-up of fibrosis in the extracellular matrix. As such, their inhibition provides a novel treatmen...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9146019/ https://www.ncbi.nlm.nih.gov/pubmed/35628342 http://dx.doi.org/10.3390/ijms23105533 |
_version_ | 1784716457501786112 |
---|---|
author | Yao, Yimin Findlay, Alison Stolp, Jessica Rayner, Benjamin Ask, Kjetil Jarolimek, Wolfgang |
author_facet | Yao, Yimin Findlay, Alison Stolp, Jessica Rayner, Benjamin Ask, Kjetil Jarolimek, Wolfgang |
author_sort | Yao, Yimin |
collection | PubMed |
description | Systemic sclerosis (SSc) is characterised by progressive multiple organ fibrosis leading to morbidity and mortality. Lysyl oxidases play a vital role in the cross-linking of collagens and subsequent build-up of fibrosis in the extracellular matrix. As such, their inhibition provides a novel treatment paradigm for SSc. A novel small molecule pan-lysyl oxidase inhibitor, PXS-5505, currently in clinical development for myelofibrosis treatment was evaluated using in vivo rodent models resembling the fibrotic conditions in SSc. Both lysyl oxidase and lysyl oxidase-like 2 (LOXL2) expression were elevated in the skin and lung of SSc patients. The oral application of PXS-5505 inhibited lysyl oxidase activity in the skin and LOXL2 activity in the lung. PXS-5505 exhibited anti-fibrotic effects in the SSc skin mouse model, reducing dermal thickness and α-smooth muscle actin. Similarly, in the bleomycin-induced mouse lung model, PXS-5505 reduced pulmonary fibrosis toward normal levels, mediated by its ability to normalise collagen/elastin crosslink formation. PXS-5505 also reduced fibrotic extent in models of the ischaemia-reperfusion heart, the unilateral ureteral obstruction kidney, and the CCl4-induced fibrotic liver. PXS-5505 consistently demonstrates potent anti-fibrotic efficacy in multiple models of organ fibrosis relevant to the pathogenesis of SSc, suggesting that it may be efficacious as a novel approach for treating SSc. |
format | Online Article Text |
id | pubmed-9146019 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-91460192022-05-29 Pan-Lysyl Oxidase Inhibitor PXS-5505 Ameliorates Multiple-Organ Fibrosis by Inhibiting Collagen Crosslinks in Rodent Models of Systemic Sclerosis Yao, Yimin Findlay, Alison Stolp, Jessica Rayner, Benjamin Ask, Kjetil Jarolimek, Wolfgang Int J Mol Sci Article Systemic sclerosis (SSc) is characterised by progressive multiple organ fibrosis leading to morbidity and mortality. Lysyl oxidases play a vital role in the cross-linking of collagens and subsequent build-up of fibrosis in the extracellular matrix. As such, their inhibition provides a novel treatment paradigm for SSc. A novel small molecule pan-lysyl oxidase inhibitor, PXS-5505, currently in clinical development for myelofibrosis treatment was evaluated using in vivo rodent models resembling the fibrotic conditions in SSc. Both lysyl oxidase and lysyl oxidase-like 2 (LOXL2) expression were elevated in the skin and lung of SSc patients. The oral application of PXS-5505 inhibited lysyl oxidase activity in the skin and LOXL2 activity in the lung. PXS-5505 exhibited anti-fibrotic effects in the SSc skin mouse model, reducing dermal thickness and α-smooth muscle actin. Similarly, in the bleomycin-induced mouse lung model, PXS-5505 reduced pulmonary fibrosis toward normal levels, mediated by its ability to normalise collagen/elastin crosslink formation. PXS-5505 also reduced fibrotic extent in models of the ischaemia-reperfusion heart, the unilateral ureteral obstruction kidney, and the CCl4-induced fibrotic liver. PXS-5505 consistently demonstrates potent anti-fibrotic efficacy in multiple models of organ fibrosis relevant to the pathogenesis of SSc, suggesting that it may be efficacious as a novel approach for treating SSc. MDPI 2022-05-16 /pmc/articles/PMC9146019/ /pubmed/35628342 http://dx.doi.org/10.3390/ijms23105533 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Yao, Yimin Findlay, Alison Stolp, Jessica Rayner, Benjamin Ask, Kjetil Jarolimek, Wolfgang Pan-Lysyl Oxidase Inhibitor PXS-5505 Ameliorates Multiple-Organ Fibrosis by Inhibiting Collagen Crosslinks in Rodent Models of Systemic Sclerosis |
title | Pan-Lysyl Oxidase Inhibitor PXS-5505 Ameliorates Multiple-Organ Fibrosis by Inhibiting Collagen Crosslinks in Rodent Models of Systemic Sclerosis |
title_full | Pan-Lysyl Oxidase Inhibitor PXS-5505 Ameliorates Multiple-Organ Fibrosis by Inhibiting Collagen Crosslinks in Rodent Models of Systemic Sclerosis |
title_fullStr | Pan-Lysyl Oxidase Inhibitor PXS-5505 Ameliorates Multiple-Organ Fibrosis by Inhibiting Collagen Crosslinks in Rodent Models of Systemic Sclerosis |
title_full_unstemmed | Pan-Lysyl Oxidase Inhibitor PXS-5505 Ameliorates Multiple-Organ Fibrosis by Inhibiting Collagen Crosslinks in Rodent Models of Systemic Sclerosis |
title_short | Pan-Lysyl Oxidase Inhibitor PXS-5505 Ameliorates Multiple-Organ Fibrosis by Inhibiting Collagen Crosslinks in Rodent Models of Systemic Sclerosis |
title_sort | pan-lysyl oxidase inhibitor pxs-5505 ameliorates multiple-organ fibrosis by inhibiting collagen crosslinks in rodent models of systemic sclerosis |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9146019/ https://www.ncbi.nlm.nih.gov/pubmed/35628342 http://dx.doi.org/10.3390/ijms23105533 |
work_keys_str_mv | AT yaoyimin panlysyloxidaseinhibitorpxs5505amelioratesmultipleorganfibrosisbyinhibitingcollagencrosslinksinrodentmodelsofsystemicsclerosis AT findlayalison panlysyloxidaseinhibitorpxs5505amelioratesmultipleorganfibrosisbyinhibitingcollagencrosslinksinrodentmodelsofsystemicsclerosis AT stolpjessica panlysyloxidaseinhibitorpxs5505amelioratesmultipleorganfibrosisbyinhibitingcollagencrosslinksinrodentmodelsofsystemicsclerosis AT raynerbenjamin panlysyloxidaseinhibitorpxs5505amelioratesmultipleorganfibrosisbyinhibitingcollagencrosslinksinrodentmodelsofsystemicsclerosis AT askkjetil panlysyloxidaseinhibitorpxs5505amelioratesmultipleorganfibrosisbyinhibitingcollagencrosslinksinrodentmodelsofsystemicsclerosis AT jarolimekwolfgang panlysyloxidaseinhibitorpxs5505amelioratesmultipleorganfibrosisbyinhibitingcollagencrosslinksinrodentmodelsofsystemicsclerosis |